13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Regulation of NCAPG by miR‐99a‐3p (passenger strand) inhibits cancer cell aggressiveness and is involved in CRPC

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Effective treatments for patients with castration‐resistant prostate cancer ( CRPC) have not yet been established. Novel approaches for identification of putative therapeutic targets for CRPC are needed. Analyses of RNA sequencing of micro RNA (mi RNA) expression revealed that miR‐99a‐3p (passenger strand) is significantly downregulated in several types of cancers. Here, we aimed to identify novel miR‐99a‐3p regulatory networks and therapeutic targets for CRPC. Ectopic expression of miR‐99a‐3p significantly inhibited cancer cell proliferation, migration, and invasion in PCa cells. Non‐ SMC condensin I complex subunit G ( NCAPG ) was a direct target of miR‐99a‐3p in PCa cells. Overexpression of NCAPG was detected in CRPC clinical specimens and was significantly associated with shorter disease‐free survival and advanced clinical stage. Knockdown of NCAPG inhibited cancer cell aggressiveness. The passenger strand miR‐99a‐3p acted as an antitumor mi RNA in naïve PCa and CRPC. NCAPG was regulated by miR‐99a‐3p, and its overexpression was involved in CRPC pathogenesis. Involvement of passenger strand of mi RNA in cancer pathogenesis is novel concept, and identification of antitumor mi RNA regulatory networks in CRPC might be provided novel prognostic markers and therapeutic targets for this disease.

          Related collections

          Most cited references37

          • Record: found
          • Abstract: found
          • Article: not found

          Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

          The cBioPortal for Cancer Genomics (http://cbioportal.org) provides a Web resource for exploring, visualizing, and analyzing multidimensional cancer genomics data. The portal reduces molecular profiling data from cancer tissues and cell lines into readily understandable genetic, epigenetic, gene expression, and proteomic events. The query interface combined with customized data storage enables researchers to interactively explore genetic alterations across samples, genes, and pathways and, when available in the underlying data, to link these to clinical outcomes. The portal provides graphical summaries of gene-level data from multiple platforms, network visualization and analysis, survival analysis, patient-centric queries, and software programmatic access. The intuitive Web interface of the portal makes complex cancer genomics profiles accessible to researchers and clinicians without requiring bioinformatics expertise, thus facilitating biological discoveries. Here, we provide a practical guide to the analysis and visualization features of the cBioPortal for Cancer Genomics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            MicroRNAs in cancer: small molecules with a huge impact.

            Every cellular process is likely to be regulated by microRNAs, and an aberrant microRNA expression signature is a hallmark of several diseases, including cancer. MicroRNA expression profiling has indeed provided evidence of the association of these tiny molecules with tumor development and progression. An increasing number of studies have then demonstrated that microRNAs can function as potential oncogenes or oncosuppressor genes, depending on the cellular context and on the target genes they regulate. Here we review our current knowledge about the involvement of microRNAs in cancer and their potential as diagnostic, prognostic, and therapeutic tools.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes.

              In the Drosophila and mammalian RNA interference pathways, siRNAs direct the protein Argonaute2 (Ago2) to cleave corresponding mRNA targets, silencing their expression. Ago2 is the catalytic component of the RNAi enzyme complex, RISC. For each siRNA duplex, only one strand, the guide, is assembled into the active RISC; the other strand, the passenger, is destroyed. An ATP-dependent helicase has been proposed first to separate the two siRNA strands, then the resulting single-stranded guide is thought to bind Ago2. Here, we show that Ago2 instead directly receives the double-stranded siRNA from the RISC assembly machinery. Ago2 then cleaves the siRNA passenger strand, thereby liberating the single-stranded guide. For siRNAs, virtually all RISC is assembled through this cleavage-assisted mechanism. In contrast, passenger-strand cleavage is not important for the incorporation of miRNAs that derive from mismatched duplexes.
                Bookmark

                Author and article information

                Contributors
                naoseki@faculty.chiba-u.jp
                Journal
                Cancer Med
                Cancer Med
                10.1002/(ISSN)2045-7634
                CAM4
                Cancer Medicine
                John Wiley and Sons Inc. (Hoboken )
                2045-7634
                02 April 2018
                May 2018
                : 7
                : 5 ( doiID: 10.1002/cam4.2018.7.issue-5 )
                : 1988-2002
                Affiliations
                [ 1 ] Department of Functional Genomics Chiba University Graduate School of Medicine Chiba Japan
                [ 2 ] Department of Urology Chiba University Graduate School of Medicine Chiba Japan
                [ 3 ] Department of Urology Teikyo University Chiba Medical Center Ichihara Japan
                [ 4 ] Department of Pathology Teikyo University Chiba Medical Center Ichihara Japan
                Author notes
                [*] [* ] Correspondence

                Naohiko Seki, Department of Functional Genomics, Chiba University Graduate School of Medicine, 1‐8‐1 Inohana Chuo‐ku, Chiba 260‐8670, Japan. Tel: +81‐43‐226‐2971; Fax: +81‐43‐227‐3442; E‐mail: naoseki@ 123456faculty.chiba-u.jp

                Author information
                http://orcid.org/0000-0002-3888-9576
                Article
                CAM41455
                10.1002/cam4.1455
                5943442
                29608247
                c9779908-78a2-47ea-a1d4-ebba1c431186
                © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 19 December 2017
                : 26 February 2018
                : 28 February 2018
                Page count
                Figures: 7, Tables: 2, Pages: 15, Words: 8139
                Funding
                Funded by: KAKENHI grants
                Award ID: 15K10801(C)
                Award ID: 16H05462(B)
                Award ID: 16K20125(B)
                Award ID: 17K11160(C)
                Award ID: 17K16777(B)
                Award ID: 17K16778(B)
                Categories
                Original Research
                Cancer Biology
                Original Research
                Custom metadata
                2.0
                cam41455
                May 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.7.2 mode:remove_FC converted:09.05.2018

                Oncology & Radiotherapy
                castration‐resistant prostate cancer,microrna,mir‐99a‐3p,mir‐99a‐5p,non‐smc condensin i complex subunit g

                Comments

                Comment on this article